Koninklijke Philips N.V. (NYSE:PHG) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Koninklijke Philips N.V. has received an average rating of "Moderate Buy" from five research firms, with views ranging from a sell rating to a strong buy.
• In its latest earnings report, the company exceeded analysts' expectations with revenue of $5.05 billion and earnings per share of $0.41.
• Institutional investors are actively trading the stock, with notable increases in holdings from firms like QRG Capital Management and Cerity Partners.

Koninklijke Philips N.V. (NYSE:PHG - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company.

A number of analysts recently commented on the stock. Weiss Ratings reissued a "sell (d+)" rating on shares of Koninklijke Philips in a report on Saturday, September 27th. Wall Street Zen downgraded shares of Koninklijke Philips from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd.

Koninklijke Philips Price Performance

PHG stock traded up $0.24 during trading on Friday, reaching $28.01. 1,021,100 shares of the company were exchanged, compared to its average volume of 641,004. The company has a market cap of $26.97 billion, a P/E ratio of 147.39, a PEG ratio of 0.74 and a beta of 0.82. Koninklijke Philips has a 52-week low of $21.48 and a 52-week high of $32.62. The stock's 50 day moving average price is $27.43 and its 200 day moving average price is $25.19. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.81 and a current ratio of 1.26.

Koninklijke Philips (NYSE:PHG - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The technology company reported $0.41 EPS for the quarter, topping analysts' consensus estimates of $0.29 by $0.12. The firm had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $4.35 billion. Koninklijke Philips had a net margin of 1.00% and a return on equity of 11.95%. As a group, analysts predict that Koninklijke Philips will post 1.63 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Koninklijke Philips

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. QRG Capital Management Inc. raised its position in Koninklijke Philips by 11.0% during the first quarter. QRG Capital Management Inc. now owns 142,595 shares of the technology company's stock worth $3,622,000 after acquiring an additional 14,090 shares during the last quarter. Aurora Private Wealth Inc. acquired a new position in Koninklijke Philips during the first quarter worth about $1,695,000. Cerity Partners LLC raised its position in Koninklijke Philips by 30.6% during the first quarter. Cerity Partners LLC now owns 80,767 shares of the technology company's stock worth $2,051,000 after acquiring an additional 18,906 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Koninklijke Philips by 2.5% during the first quarter. Dimensional Fund Advisors LP now owns 4,396,095 shares of the technology company's stock worth $111,662,000 after acquiring an additional 106,044 shares during the last quarter. Finally, HB Wealth Management LLC acquired a new position in Koninklijke Philips during the first quarter worth about $333,000. Institutional investors and hedge funds own 13.67% of the company's stock.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.